An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder
NCT ID: NCT00057226
Last Updated: 2015-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
365 participants
INTERVENTIONAL
2003-03-31
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder
NCT00057213
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
NCT00057239
Study Of GW679769 In Major Depressive Disorder
NCT00102492
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
NCT00048204
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)
NCT00413023
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radafaxine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Duration of current depressive episode 12 weeks - 24 months
* Patients can read and write at a level sufficient to provide a signed consent
* If female, patients must be practicing an acceptable method of birth control
Exclusion Criteria
* Patients have not responded to two or more adequate courses of antidepressant therapy
* Patients cannot be currently abusing illicit drugs or alcohol
* Patients are not currently receiving psychotherapy
* Patients have received electroconvulsive therapy within 6 months prior to screening
* Patients are pregnant or lactating
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Cerritos, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
GSK Investigational Site
Boynton Beach, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Marietta, Georgia, United States
GSK Investigational Site
Libertyville, Illinois, United States
GSK Investigational Site
Oakbrook Terrace, Illinois, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
Lafayette, Indiana, United States
GSK Investigational Site
Shreveport, Louisiana, United States
GSK Investigational Site
Rockville, Maryland, United States
GSK Investigational Site
Saint Charles, Missouri, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Toledo, Ohio, United States
GSK Investigational Site
Memphis, Tennessee, United States
GSK Investigational Site
Nashville, Tennessee, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Bellevue, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OHB20003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.